HECAM

Scientific and industrial excellence in the fight against liver cancer

Detection

Stratification of populations with predispositions HCC development through the development of biomarkers allowing a risk score. Development of protein markers for early detection of HCC.

Characterization

Development of innovative imaging methods of HCC multi-parameter characterization allowing a precise diagnosis as well as an adapted therapeutic follow-up.

Treatment

Tools and techniques development for an effective treatment of HCC in surgery and interventional radiology (interventional imaging techniques, fluorescence imaging, focused ultrasound ablation, chemoembolization agent, etc.).

About HECAM

HECAM gathers scientific and industrial excellence in research on hepatocellular carcinoma (the primary cancer of the liver). The Consortium's ambition is to address the entire disease cycle through the development of advanced technologies in the areas of stratification of at-risk populations, ultra-early detection of HCC, multi-parametric characterization of tumor and surgical as well as interventional radiology techniques.

With a duration of 5 years, the HECAM project has a budget of 34.6 million euros, of which 18.2m€ are financed by Bpifrance under the 4th Call “Appel à Projets Structurant pour la Compétitivité”. Led by GE Healthcare, the project gathers 12 partners including 7 SMEs (BioPredictive, CarThera, IntegraGen, BioSIMS, EDAP-TMS, Fluoptics and Intrasense), 2 major healthcare giants (GE Healthcare and Guerbet) as well as 3 academic partners (AP-HP, Inserm and Gustave Roussy).    

HECAM aims to improve the management of HCC in order to reduce the mortality rate due to this disease, often caused by a late diagnosis, while at the same time, developing the French competitiveness around HCC research.

Recent Careers

No job offers available.

Partners

Inserm
Assistance Publique
Carthera
GE
Fluoptics
EDAP TMS
Integragen
Bio Predictive
Guerbet
Intrasense
Gustave Roussy